Solid Biosciences (NASDAQ:SLDB) was downgraded by equities researchers at JPMorgan Chase from a “neutral” rating to an “underweight” rating in a note issued to investors on Thursday, March 15th, MarketBeat reports. They currently have a $28.00 target price on the stock. JPMorgan Chase’s price objective points to a potential upside of 193.50% from the stock’s previous close.
Several other analysts have also recently issued reports on SLDB. Goldman Sachs initiated coverage on Solid Biosciences in a report on Tuesday, February 20th. They issued a “neutral” rating and a $31.00 target price for the company. Leerink Swann assumed coverage on Solid Biosciences in a report on Tuesday, February 20th. They set an “outperform” rating and a $36.00 price target for the company. Instinet assumed coverage on Solid Biosciences in a research note on Tuesday, February 20th. They set a “buy” rating and a $52.00 target price on the stock. Nomura assumed coverage on Solid Biosciences in a research note on Tuesday, February 20th. They set a “buy” rating and a $52.00 target price on the stock. Finally, Chardan Capital assumed coverage on Solid Biosciences in a research note on Wednesday, February 21st. They set a “buy” rating and a $40.00 target price on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $33.67.
NASDAQ SLDB opened at $9.54 on Thursday. The firm has a market capitalization of $339.87 and a P/E ratio of -3.31. Solid Biosciences has a one year low of $6.83 and a one year high of $33.74.
In other Solid Biosciences news, Director Life Sciences Maste Perceptive bought 1,020,000 shares of the business’s stock in a transaction dated Tuesday, January 30th. The shares were acquired at an average price of $16.22 per share, with a total value of $16,544,400.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.
COPYRIGHT VIOLATION NOTICE: “Solid Biosciences (SLDB) Downgraded by JPMorgan Chase to “Underweight”” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/08/solid-biosciences-sldb-lowered-to-underweight-at-jpmorgan-chase-co.html.
Solid Biosciences Company Profile
Solid Biosciences Inc, a life science company, engages in identifying and developing various therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, an adeno-associated viral vector-mediated gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles.
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.